Kazia Suffers Brain Cancer Drug Setback But All Hope Not Lost
Paxalisib Pulled From GBM Platform Study
Executive Summary
News that the Australian biotech's paxalisib did not meet pre-defined criteria to continue into the second stage of a major glioblastoma platform trial saw Kazia's stock crash, but investor reaction appears to be excessive.